COMMUNIQUÉS West-GlobeNewswire

-
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
09/01/2025 -
Voting Rights and Shares Capital of the Company
09/01/2025 -
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
09/01/2025 -
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025
09/01/2025 -
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
09/01/2025 -
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
09/01/2025 -
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
09/01/2025 -
BioV Life Science and Regenerative Medicine International Summit Successfully Concludes, Leading the Future of Regenerative Medicine
09/01/2025 -
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
09/01/2025 -
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/01/2025 -
Partnering to Save Lives, NMDP and the American Football Coaches Association Promote Student Athlete Philanthropy
09/01/2025 -
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
09/01/2025 -
LifeLabs’ President and CEO, Charles Brown, named one of the “Top 50 Healthcare Technology CEOs of 2024”
09/01/2025 -
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
09/01/2025 -
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
09/01/2025 -
New Book "Prescribed Malnutrition: An Oncology Nutrition Narrative Review" Announces Critical Insights into Cancer Nutrition Misconceptions
09/01/2025 -
Cytosurge Announces Strategic Leadership Transition
09/01/2025 -
H.H.C. Group Successfully Completes URAC Monitoring Validation Review as Independent Review Organization
09/01/2025 -
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
09/01/2025
Pages